Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
248 hedge funds and large institutions have $1.11B invested in Catalyst Pharmaceutical in 2023 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 83 increasing their positions, 83 reducing their positions, and 46 closing their positions.
220% more call options, than puts
Call options by funds: $4.23M | Put options by funds: $1.32M
0% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 83
4% less funds holding
Funds holding: 259 → 248 (-11)
5.51% less ownership
Funds ownership: 83.19% → 77.68% (-5.5%)
20% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 46
25% less capital invested
Capital invested by funds: $1.47B → $1.11B (-$365M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$27.5M |
| 2 |
Man Group
London,
United Kingdom
|
+$12M |
| 3 |
BlackRock
New York
|
+$7.07M |
| 4 |
Barclays
London,
United Kingdom
|
+$6.75M |
| 5 |
RA
Royce & Associates
New York
|
+$6.1M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$31.1M |
| 2 |
Two Sigma Investments
New York
|
-$16.7M |
| 3 |
Millennium Management
New York
|
-$15M |
| 4 |
Two Sigma Advisers
New York
|
-$13.6M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$12.6M |
CPRX Hedge Fund Activity: Q2 2023 in Review
248 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2023, worth a combined $1.11B — down 25% from $1.47B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of CPRX and 37 opened new positions — a net loss of 9 holders — while 83 trimmed existing stakes and 83 added.
The largest buyer was State Street, adding an estimated $27.5M. The largest seller was Deerfield Management, cutting an estimated $31.1M.
- 248 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2023, down from 259 in Q1 2023.
- Funds reported $1.11B of Catalyst Pharmaceutical stock for Q2 2023, down 25% quarter-over-quarter.
- 37 funds opened new Catalyst Pharmaceutical positions in Q2 2023 and 46 closed out, a net change of -9 holders.
- The largest Catalyst Pharmaceutical buyer in Q2 2023 was State Street, an estimated $27.5M added.
- The largest Catalyst Pharmaceutical seller in Q2 2023 was Deerfield Management, an estimated $31.1M sold.
Based on aggregated 13F filings for Q2 2023.